Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Pitcher, Bethany ^a   Khoja, Leila ^a   Hamilton, Robert J ^b   Abdallah, Kald ^c   Pintilie, Melania ^d   Joshua, Anthony M ^a,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Project Data Sphere LLC   (United States)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; LOW MOLECULAR WEIGHT HEPARIN; METFORMIN; PROSTATE SPECIFIC ANTIGEN; WARFARIN; ANTINEOPLASTIC AGENT; TAXOID;

AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREDICTION; PROCESS OPTIMIZATION; PROJECT DATA SPHERE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE; BLOOD; DISEASE COURSE; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; THEORETICAL MODEL; TREATMENT OUTCOME; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; METFORMIN; MODELS, THEORETICAL; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; ROC CURVE; TAXOIDS; TREATMENT OUTCOME; WARFARIN;

EID: 85011339681     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170544     Document Type: Article

References (34)

1. Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol. 2015; 25(3):232-7. doi:10.1097/MOU.0000000000000157 PMID: 25692723.
2. Patrikidou A, Loriot Y, Eymard JC, Albiges L, Massard C, Ileana E, et al. Who dies from prostate cancer? Prostate Cancer Prostatic Dis. 2014; 17(4):348-52. doi:10.1038/pcan.2014.35 PMID: 25311767.
3. Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, et al. Natural history of surgically treated high-risk prostate cancer. Urol Oncol. 2015; 33(4):163 e7-13.
4. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the Oncotype DX prostate cancer assaya clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013; 14:690. PubMed Central PMCID: PMC4007703. doi:10.1186/1471-2164-14-690 PMID: 24103217.
5. Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. The Journal of urology. 2014; 192(2):409-14. doi:10.1016/j.juro.2014.02.003 PMID: 24508632.
6. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clinical cancer research: An official journal of the American Association for Cancer Research. 2007; 13(21):6396-403.
7. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32(7):671-7. PubMed Central PMCID: PMC3927736.
8. Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, Bianchini D, et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol. 2013; 64(2):300-6. doi:10.1016/j.eururo.2012.12.029 PMID: 23313031.
9. Halabi S, Kelly WK, Zhou H, Armstrong AJ, Quinn D, Fizazi K, et al. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-Analysis of five phase III trials. ASCO Meeting Abstracts. 2014;32(15-suppl):5002.
10. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002; 20(19):3972-82.
11. Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-Tolymphocyte ratio. Cancer. 2014; 120(21):3346-52. doi:10.1002/cncr.28890 PMID: 24995769.
12. Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, et al. Prognostic impact of the neutrophil-To-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clinical genitourinary cancer. 2014; 12(5):317-24. doi:10.1016/j.clgc.2014.03.005 PMID: 24806399.
13. Project Data Sphere [online database]. Available from: https://www.projectdatasphere.org/projectdatasphere/html/home.html.
14. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56(2):337-44. PMID: 10877287.
15. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine. 2004; 351(15):1502-12. doi:10.1056/NEJMoa040720 PMID: 15470213.
16. Seah JA, Leibowitz-Amit R, Atenafu EG, Alimohamed N, Knox JJ, Joshua AM, et al. Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer. Clinical genitourinary cancer. 2015.
17. Inoue D, Ozaka M, Matsuyama M, Yamada I, Takano K, Saiura A, et al. Prognostic value of neutrophillymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: A retrospective study in a single institute in Japan. Jpn J Clin Oncol. 2015; 45(1):61-6. doi:10.1093/jjco/hyu159 PMID: 25341546.
18. Kumar R, Geuna E, Michalarea V, Guardascione M, Naumann U, Lorente D, et al. The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials. British journal of cancer. 2015; 112(7):1157-65. PubMed Central PMCID: PMC4385959. doi:10.1038/bjc.2015.67 PMID: 25719834.
19. Park JC, Pratz CF, Tesfaye A, Brodsky RA, Antonarakis ES. The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer. Clinical genitourinary cancer. 2015; 13(1):32-8. PubMed Central PMCID: PMC4332782. doi:10.1016/j.clgc.2014.04.008 PMID: 24999166.
20. James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. The lancet oncology. 2012; 13 (5):549-58. PubMed Central PMCID: PMC3398767. doi:10.1016/S1470-2045(12)70088-8 PMID: 22452894.
21. Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 2013; 332(2):313- 24. doi:10.1016/j.canlet.2011.01.012 PMID: 21345578.
22. Bieniek J, Childress C, Swatski MD, Yang W. COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins. Prostate. 2014; 74(10):999-1011. doi:10.1002/pros.22815 PMID: 24802614.
23. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi D, et al. Metformin in chemotherapy-naive castration-resistant prostate cancer: A multicenter phase 2 trial (SAKK 08/09). Eur Urol. 2014; 66(3):468-74. doi:10.1016/j.eururo.2013.12.057 PMID: 24412228.
24. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014; 3:e02242. PubMed Central PMCID: PMC4017650. doi:10.7554/eLife.02242 PMID: 24843020.
25. Loubiere C, Goiran T, Laurent K, Djabari Z, Tanti JF, Bost F. Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. Oncotarget. 2015; 6(17):15652-61. doi:10.18632/oncotarget.3404PMID: 26002551.
26. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. doi:10.1038/sj.onc.1211024 PMID: 18212742.
27. Kato H, Sekine Y, Furuya Y, Miyazawa Y, Koike H, Suzuki K. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 2015; 461(1):115-21. doi:10.1016/j.bbrc.2015.03.178 PMID: 25862373.
28. Demir U, Koehler A, Schneider R, Schweiger S, Klocker H. Metformin anti-Tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells. BMC Cancer. 2014; 14:52. PubMed Central PMCID: PMC3929757. doi:10.1186/1471-2407-14-52PMID: 24484909.
29. Tagalakis V, Tamim H, Blostein M, Hanley JA, Kahn SR. Risk of prostate cancer death in long-Term users of warfarin: A population-based case-control study. Cancer Causes Control. 2013; 24(6):1079- 85. doi:10.1007/s10552-013-0185-1 PMID: 23494728.
30. Stopsack KH, Greenberg AJ, Mucci LA. Common medications and prostate cancer mortality: A review. World J Urol. 2016.
31. O'Rorke MA, Murray LJ, Hughes CM, Cantwell MM, Cardwell CR. The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: A population-based cohort study using the Clinical Practice Research Datalink. Cancer Causes Control. 2015; 26(3):355-66. doi:10.1007/s10552-014-0511-2PMID: 25534917.
32. Francini E, Petrioli R, Rossi G, Laera L, Roviello G. PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castrationresistant prostate cancer: An analysis of 22 trials. Tumour Biol. 2014; 35(11):10601-7. doi:10.1007/s13277-014-2559-8 PMID: 25195134.
33. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(23):3860-6. PubMed Central PMCID: PMC2654813.
34. Manzano JG, Luo R, Elting LS, George M, Suarez-Almazor ME. Patterns and predictors of unplanned hospitalization in a population-based cohort of elderly patients with GI cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32(31):3527-33. PubMed Central PMCID: PMC4209103.